When was RareStone Group founded?

RareStone Group was founded in 2003.

Where is RareStone Group located?

RareStone Group is headquartered in Huangpu, China.

Who is the current CEO of RareStone Group?

Shawn Xiang of RareStone Group.

How many employees does RareStone Group have?

As of Sep 30, 2026, the latest employee count at RareStone Group is 20.

Where does RareStone Group rank among its competitors?

RareStone Group ranks 11th amongst 200 active competitors, of which 11 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strive Pharmacy, which secured $298K in Nov, 2019.

Who are the top competitors of RareStone Group?

RareStone Group's top competitors include Fagron, Pharmacychain366 and Managed Healthcare Pharmacy. Among them, Strive Pharmacy secured the most recent funding round in November, 2019.

RareStone Group - 2026 Company Profile, Team, Funding & Competitors

RareStone Group is a funded company based in Huangpu (China), founded in 2003. It operates as a Provider of network and treatments to individuals and their families affected by rare diseases drugs. The company has 200 active competitors, including 11 funded and 33 that have exited. Its top competitors include companies like Fagron, Pharmacychain366 and Managed Healthcare Pharmacy.

Company Details

Website: rarestonegroup.com
Email ID: *****@rarestonegroup.com
Phone Number: +86 **********

Key Metrics

Founded Year

2003

Location

Huangpu, China

Stage

Funding Raised

Investors

F-Prime Capital & 4 more

Ranked

11^th among 200 active competitors

Employee Count

20 as on Sep 30, 2026

Investment & Acquisitions

Metalcore

Similar Companies

Fagron & 201 more

View RareStone Group's full profile

RareStone Group is a funded company. RareStone Group has 5 institutional investors.

View details of RareStone Group's funding rounds and investors

RareStone Group's employee count trend

RareStone Group has 20 employees as of Sep 26. Here is RareStone Group's employee count trend over the years:

Employee count trend for RareStone Group

Uncover RareStone Group's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RareStone Group include Fagron, Pharmacychain366 and Managed Healthcare Pharmacy. Here is the list of Top 10 competitors of RareStone Group, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Fagron 1990, Rotterdam (Netherlands), Public	Provider of pharmaceutical compounding, sterile outsourcing services, and related pharmaceutical products	-	Triodos Investment Management, Baltisse & 2 others	48/100
2nd	Pharmacychain366 Moscow (Russia), Public	Chain of pharmacies	-	-	42/100
3rd	Managed Healthcare Pharmacy 2002, Eugene (United States), Acquired	Provider of pharmacy services for long-term care facilities and group homes	-	-	41/100
4th	Strive Pharmacy 2018, Gilbert (United States), Seed	Provider of drug compounding services	$298K	-	40/100
5th	Tailor Made Compounding 2015, Nicholasville (United States), Acquired	Provider of compounding and nutrition services	-	Weller Equity Partners	40/100
6th	Srxltc Ridgefield Park (United States), Unfunded	Provider of pharmacy services to long-term care facilities.	-	-	38/100
7th	Pharmedium 2003, Lake Forest (United States), Acquired	Online pharmacy providing affordable medications, prescription fulfillment, and healthcare products	-	Clayton Dubilier & Rice, Oak HC/FT & 3 others	37/100
8th	Medisca 1989, Montreal (Canada), Unfunded	Provider of pharmaceutical compounding products, equipment, devices, and quality-assured ingredients for pharmacists	-	-	37/100
9th	Medac 1970, Wedel (Germany), Funding Raised	Manufacturer of drugs	-	-	35/100
10th	Gemini Health 2014, Sausalito (United States), Series A	Provider of healthcare drug cost reduction services	$7.8M	-	33/100
11th	RareStone Group 2003, Huangpu (China), Funding Raised	Provider of network and treatments to individuals and their families affected by rare diseases drugs	-	F-Prime Capital, 3H Health Investment & 3 others	29/100